Today, research increasingly focuses on ways to prevent the onset of Alzheimer’s dementia in the first place. The public-private European Prevention of Alzheimer’s Dementia (EPAD) project pioneered a novel, more flexible approach to clinical trials of drugs designed to prevent Alzheimer’s disease dementia. Using an adaptive trial design should deliver better results faster and at lower cost.
A key project outcome is the open access EPAD database, publicly available to the research community. The Longitudinal Cohort Study (LCS) has screened over 2,000 participants and collected a wide range of cognitive, clinical, neuroimaging and biomarker data to help further our understanding of the early stages of Alzheimer’s disease. To access the data, you will need to make an online request via EPAD LCS Research Access Process. To find how to apply and learn what data is available in the EPAD data releases before you apply, visit the EPAD website here.
The LCS was initiated and the first participant screened in May 2016. Screening into the LCS was stopped on 29 February 2020 and a total of 2,096 participants had been screened. Of these 217 were screen failures and 215 have withdrawn.
The LCS is listed in Neuronet’s Asset Map, providing a comprehensive view of the different assets resulting from the Innovative Medicines Initatives neurodegeneration research projects, including but not limited to genetic datasets, clinical cohorts and data platforms. Explore it now: https://kb.imi-neuronet.org/admin/asset_map